Company Overview

Neoparm, founded in 2001 and listed on South Korea's KOSDAQ exchange, is a specialist in derma-cosmetics — skincare products developed on the basis of dermatological science. Its portfolio of functional skincare brands, including Atopam, Real Barrier and Zeroid, has earned it a durable position in South Korea's medical-grade skincare market. Despite being a mid-sized company, Neoparm has maintained a consistent dividend policy underpinned by strong profitability and cash generation, earning it a reputation as a shareholder-friendly firm.

The company began attracting broader attention from 2024 onwards, when South Korea's financial authorities launched the "Corporate Value-Up Programme" — an initiative designed to address the chronic undervaluation of Korean-listed companies relative to their global peers (a phenomenon sometimes called the "Korea discount"). As part of this initiative, small and mid-cap healthcare and beauty firms with solid balance sheets and dividend track records were thrust into the spotlight. Neoparm, with its twin attractions of growing shareholder returns and overseas expansion, emerged as one of the more compelling candidates.

Business and Financial Performance

*Core Brands and Business Model*

Neoparm's operations divide broadly into domestic derma-cosmetics sales and international export channels. At home, it distributes products for atopic and sensitive skin through hospital and clinic networks, pharmacies, and online platforms — a route that cultivates loyal, medically-minded consumers. Internationally, a direct-to-consumer strategy centred on Amazon has begun to yield results, with brand recognition in North America reported to be rising steadily.

Analysts have forecast that quarterly revenues will surpass 40 billion won for the first time in the second quarter of 2026, driven primarily by a surge in overseas sales through Amazon. The prevailing view is that the global boom in K-beauty is providing direct momentum to Neoparm's results.

*Revenue and Profit Trends*

Year | Revenue (bn won) | Operating Profit (bn won) | Operating Margin (%) | Notes

2021 | ~82 | ~14 | ~17 | Post-COVID recovery

2022 | ~88 | ~13.5 | ~15 | Raw material cost pressure

2023 | ~95 | ~15.5 | ~16 | Export channels ramping up

2024 | ~110 | ~19 | ~17 | K-beauty tailwind

2025 | ~135 | ~23.5 | ~17 | Amazon sales accelerating

2026 (est.) | 160+ | 27+ | 17–18 | Quarterly record anticipated

*Figures are based on publicly available estimates and industry projections; some are approximations.*

*Structural Advantage: Margins That Stand Out*

Neoparm's in-house research and development capabilities allow it to own its brand portfolio outright, rather than relying on third-party contract manufacturers (OEM or ODM suppliers). This is the principal reason its operating margin — consistently around 17% — runs well above the sector average of roughly 8–10%. Its business model, which leverages the credibility of medical channels rather than heavy advertising spend, further supports cash generation.

Value-Up Milestones

*Pre-2024 — A Dividend Track Record as Foundation*

Long before the value-up programme was introduced, Neoparm had established itself as a reliable dividend payer. Its payout ratio consistently exceeded the healthcare sector average, providing the credibility needed to anchor subsequent shareholder-return discussions. Industry data published in March 2025 showed that 86% of Korean healthcare companies maintained or raised their dividends — a trend Neoparm was said to have mirrored.

*June 2024 — A Sectoral Catalyst: APR's Share Cancellation*

A significant event for the broader industry came in June 2024, when APR — a fellow cosmetics and derma-beauty company — carried out a 60 billion won share buyback and cancellation. The move ignited expectations across the KOSDAQ-listed beauty sector that shareholder returns would become more competitive. Neoparm was among the companies identified as likely to follow suit.

*March 2025 — Board Restructuring at the AGM*

The annual general meeting season of March 2025 brought visible changes to board composition across the cosmetics industry. Neoparm was reported to have restructured its board as part of a broader governance improvement effort — an initiative widely described in Korean financial media as "reshaping the boardroom to give the value-up agenda real weight."

*October 2025 — K-Beauty Boom Lifts Overseas Prospects*

During the second half of 2025, as South Korean beauty exports reached record levels, Neoparm's overseas expansion strategy came into sharper focus. Rapidly rising Amazon sales, well-matched to North American consumers' growing appetite for dermatologically validated skincare, gave investors a credible long-term growth narrative. Foreign institutional buying was reportedly beginning to flow into the stock around this period.

*June 2026 — Foreign Ownership Nearly Doubles*

By June 2026, reports indicated that foreign investors' ownership stake in Neoparm had nearly doubled compared to the prior year. Analysts attributed this to the combined appeal of the company's global growth trajectory and its shareholder-return policies. As North American direct sales through Amazon became increasingly tangible and the quarterly revenue milestone approached, Neoparm's standing as the benchmark derma-cosmetics stock on the KOSDAQ solidified.

Challenges and Assessment

*Outstanding Challenges*

Three structural issues will determine whether Neoparm can fully realise its value-up potential.

First, the absence of share buybacks and cancellations. To date, Neoparm's shareholder returns have been confined to cash dividends. Unlike APR, which has used share cancellations to directly boost per-share value, Neoparm has not yet adopted this tool. Many analysts argue that improving the company's price-to-book ratio (PBR) will require capital efficiency measures beyond dividends alone.

Second, over-reliance on a single channel. The growing dependence on North American Amazon sales creates vulnerability to changes in platform policy or intensifying competition from rival Korean beauty brands. Diversification into Europe, Japan, and South-East Asia is considered a medium-term strategic necessity.

Third, governance transparency. Despite the board restructuring, observers note that further improvements are warranted — particularly regarding the independence of non-executive directors, the expertise of the audit committee, and the accessibility of voting rights for ordinary shareholders.

*Overall Assessment*

Neoparm enters the value-up era from a relatively advantaged position: its proven profitability and brand credibility in the domestic derma-cosmetics market give it a stronger-than-average base from which to pursue capital efficiency improvements and enhanced shareholder returns. Its consistent dividend history and low debt levels underpin the sustainability of those returns. The near-doubling of foreign ownership between 2025 and 2026 can be read as a signal that global investors identified Neoparm's growth potential and shareholder-return capacity before the broader market did.

That said, its size constrains the absolute scale of shareholder returns relative to large-cap peers. As a mid-sized KOSDAQ company, its visibility in terms of value-up disclosure and compliance monitoring also remains lower than that of the major conglomerates (chaebols) driving the programme.

Controversies and Limitations

*The Limits of a Dividend-Only Approach*

Criticism has been raised that Neoparm's shareholder return framework is too narrowly focused on cash dividends. While dividends provide stability, they do not deliver the immediate share-price support that buybacks and cancellations can. With peers increasingly resorting to the latter, short-term investors have expressed frustration at Neoparm's relative caution.

*Insufficient Specificity in Value-Up Disclosures*

Since the value-up programme's launch in 2024, many listed Korean companies have voluntarily published shareholder return plans complete with quantified targets — specific PBR goals, dividend payout ratio increases, and return-on-equity (ROE) improvement roadmaps. Neoparm's disclosures in this area have been criticised for lacking comparable specificity. The directional intent is positive, but the absence of numerical commitments is said to be a concern for institutional investors monitoring compliance.

*Founder Control and Minority Shareholder Protection*

Neoparm retains an ownership structure centred on its founding family, meaning that shareholder return policies depend heavily on the goodwill of management rather than independent board oversight. Whether the board exercises genuine supervisory authority — and whether minority shareholders' interests are adequately reflected in corporate decisions — remains subject to ongoing scrutiny.

*Intensifying Global Competition*

The K-beauty growth story is compelling, but competition in the global derma-cosmetics market is stiffening. If rivalry among Korean beauty brands on Amazon intensifies, marketing costs are likely to rise, potentially eroding the margins that make Neoparm distinctive — and, by extension, its capacity for shareholder returns.

Key Metrics Summary

Year | DPS (won) | Buyback/Cancellation | Operating Profit (bn won) | PBR (x) | Foreign Ownership (%)

2021 | ~400 | Not confirmed | ~14 | ~2.0 | ~5

2022 | ~400 | Not confirmed | ~13.5 | ~1.8 | ~5

2023 | ~450 | Not confirmed | ~15.5 | ~2.0 | ~6

2024 | ~500 | Not confirmed | ~19 | ~2.2 | ~8

2025 | ~550+ | Not confirmed | ~23.5 | ~2.5 | ~10–12

2026 (est.) | Expected to rise | Under discussion | 27+ | Improvement expected | ~2x prior year

*Dividend per share, PBR, and foreign ownership figures are partly derived from press reports and industry estimates. Precise figures should be verified against official company filings.*